This week in medical device news, the LSI alumni community has been bustling with remarkable achievements. From securing new funding rounds to launching innovative products and receiving FDA clearances, these medical technology companies are paving the way to LSI Europe '24 in Portugal this September. Let's delve into the latest updates from the alumni making waves.
Access Vascular has released new data showcasing the efficacy of its MIMIX® hydrophilic biomaterial. This breakthrough material is designed to reduce bacterial adhesion and thrombus accumulation in catheters, aiming to surpass conventional catheter performance. Engineered to mimic the body’s natural chemistry, these catheters are designed to avoid the foreign body response, reducing complications.
AiM Medical Robotics announced a groundbreaking partnership with Brigham and Women's Hospital for the first human clinical study on MRI-guided device placement in the brain. Additionally, AiM is collaborating with fellow LSI alumni Synaptive Medical to integrate the Modus Nav neuro-navigation software with AiM's robotic system, a key component of this trial.
Brainomix has secured FDA clearance for its latest innovation, the Brainomix 360 e-Lung. Known for its pioneering Brainomix 360 stroke platform, the company continues to provide clinicians with comprehensive imaging solutions that enhance treatment rates and improve patient outcomes.
CorTec has been granted FDA IDE approval for an early feasibility study using its Closed-Loop Brain Interchange implant system. This study aims to explore a novel stroke rehabilitation treatment that uses cortical stimulation to enhance brain plasticity.
Deep Blue Medical has been honored with the Luis Villalobos Award from the Angel Capital Association, recognizing it as the Innovative Life Science Company of 2024. The company is aiming to revolutionize soft tissue surgery by developing advanced surgical devices designed to prevent surgery failures.
Egg Medical has partnered with Levant to introduce its EggNest Radiation Protection System to Israel. This system reduces radiation exposure by up to 97% without compromising workflows, ensuring safety for stakeholder involved in medical procedures.
OUI Medical has received a utility patent for its P-scope device – a disposable, portable handheld scope equipped with integrated camera, screen, processor, battery, and biopsy forceps. This innovative technology facilitates peritoneoscopy under local anesthesia at the point of care.
Oxford Endovascular raised £8M in a Series A funding round led by Parkwalk Advisors. The company’s novel flow-diverter, OxiFlow™️, is designed to divert blood flow away from intracranial aneurysms, reducing the risk of rupture.
Pristine Surgical has welcomed Christopher Cleary to its Board of Directors. The company is working to advance endoscopy by combining 4K single-use, digital arthroscopes with cloud-based software to make minimally invasive visualization more efficient and safer.
S2N Health closed a seed funding round led by Excelerate Health Ventures with contributions from investors including Boston Millennia Partners and Robin Hood Ventures. Additionally, the company has expanded its Board of Directors by appointing seasoned medtech entrepreneur Martha Shadan.
Shoulder Innovations has launched the InSet™ 95 Humeral Stem, aimed at improving surgical outcomes and patient recovery for those with poor bone quality. The InSet™ technology reduces glenoid implant micro-motion and simplifies surgical techniques, potentially decreasing complications and increasing implant longevity.
Valcare has commenced the AMEND™ TS European pilot study, enrolling its first two patients. This study will evaluate the safety and performance of the AMEND Trans-Septal System as a primary technique in mitral repair, either as a standalone therapy or combined with other approved technologies.
Vessl Prosthetics has appointed Tres Wright as its Go-To-Market and Sales Advisor. The company has developed a novel prosthetic socket that automatically adjusts to redistribute pressure around the leg in response to limb size changes.
Volta Medical announced positive results from its FDA IDE trial, showcasing the superiority of its AI decision support system in treating persistent atrial fibrillation. Patients treated with this system demonstrated greater freedom from documented AF at 12 months in comparison to conventional methods.
XEOS has appointed Co-Founder and CMO Vincent Keereman as CEO. The company is working to enhance outcomes in surgical oncology by leveraging molecular imaging technology in the operating room.
Stay tuned for more updates as top medical device companies like these continue to innovate and lead the way in the medtech industry. Whether it's securing new funding, achieving FDA milestones, or launching new products, medical device startups in the LSI alumni network are making strides in transforming healthcare.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved.
